Evercyte is happy to introduce the EVscale™ platform

April 29th, 2024, Vienna, Austria

The collaborative effort of Evercyte, Phoenestra, and TAmiRNA has yielded the EVscale™ platform, poised to offer a comprehensive solution tailored for pharmaceutical and biotech manufacturers seeking exosomes and EVs on a commercial scale. This platform will empower our partners to tailor their projects precisely, from selecting cells with utmost specificity, conducting thorough EV characterization, to achieving highly efficient and scalable EV production, and ultimately linking EV biological functions to RNA and protein EV components.

Click here to read the press release.

Browse Evercyte’s extensive portfolio of EV production cell lines which can be grown without limitations in vitro while maintaining cell type-specific markers and functions, and can be used for GMP-production of EVs.